EMA Issues Drug Safety Reminders

Article

The agency’s safety committee is reviewing hydroxyprogesterone medicines and issuing a reminder on safety issues regarding fluoroquinolone antibiotics.

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) met on May 10–12, 2023 to review medicines containing hydroxyprogesterone due to safety and effectiveness concerns. Hydroxyprogesterone caproate is available in the European Union and is given by injection to prevent pregnancy loss or premature birth. These medicines are also given in some countries to treat various gynecological disorders, according to the agency.

The French medicines agency requested PRAC review the medicines after a study suggested patients exposed to the drugs may have an increased risk of cancer that would increase when the drug was used in the first trimester of pregnancy and with the number of injections.

PRAC also issued a reminder about the risks associated with the use of fluoroquinolone antibiotics and said they should not be used to treat infections that might get better without treatment or to treat non-bacterial infections or mild bacterial infections. The restrictions imposed on these medicines were a result of a study that showed the risk of disabling, long-lasting side effects.

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes